Gut microbiota and multiple sclerosis: a potential diagnostic and prognostic marker?
作者信息
Zoledziewska Magdalena, Lorefice Lorena
机构信息
Institute of Genetic and Biomedical Research (IRGB), Italian National Research Council (CNR), Monserrato, Italy.
Multiple Sclerosis Center, ASL Cagliari, Department of Medical Sciences and Public Health, Binaghi Hospital, University of Cagliari, Cagliari, Italy.
出版信息
Neurodegener Dis Manag. 2024;14(6):189-192. doi: 10.1080/17582024.2024.2435249. Epub 2024 Nov 27.
Abstract
摘要
相似文献
1
Gut microbiota and multiple sclerosis: a potential diagnostic and prognostic marker?肠道微生物群与多发性硬化症：一种潜在的诊断和预后标志物？
Neurodegener Dis Manag. 2024;14(6):189-192. doi: 10.1080/17582024.2024.2435249. Epub 2024 Nov 27.
2
Impact of Disease-Modifying Therapies on Gut-Brain Axis in Multiple Sclerosis.疾病修饰疗法对多发性硬化症肠-脑轴的影响
Medicina (Kaunas). 2023 Dec 20;60(1):6. doi: 10.3390/medicina60010006.
3
Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.多发性硬化症的疾病修饰治疗：对肠道微生物群的影响。
Mult Scler Relat Disord. 2023 May;73:104671. doi: 10.1016/j.msard.2023.104671. Epub 2023 Mar 26.
4
Gut Microbiota as a Potential Predictive Biomarker in Relapsing-Remitting Multiple Sclerosis.肠道微生物群作为复发性缓解型多发性硬化症的潜在预测性生物标志物。
Genes (Basel). 2022 May 23;13(5):930. doi: 10.3390/genes13050930.
5
The gut microbiota in multiple sclerosis varies with disease activity.多发性硬化症患者的肠道微生物群与疾病活动度有关。
Genome Med. 2023 Jan 5;15(1):1. doi: 10.1186/s13073-022-01148-1.
6
Interaction of the Gut Microbiome and Immunity in Multiple Sclerosis: Impact of Diet and Immune Therapy.肠道微生物组与多发性硬化症中的免疫相互作用：饮食和免疫治疗的影响。
Int J Mol Sci. 2023 Sep 29;24(19):14756. doi: 10.3390/ijms241914756.
7
Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.肠道微生物群与多发性硬化症的变化：系统评价。
Int J Environ Res Public Health. 2023 Mar 6;20(5):4624. doi: 10.3390/ijerph20054624.
8
Multiple Sclerosis and Microbiome.多发性硬化症与微生物组。
Biomolecules. 2022 Mar 11;12(3):433. doi: 10.3390/biom12030433.
9
Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.用于治疗多发性硬化症和肠道微生物组的疾病修正疗法：系统评价。
J Neurol. 2024 Mar;271(3):1108-1123. doi: 10.1007/s00415-023-12107-0. Epub 2023 Dec 11.
10
Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis.多发性硬化症患者使用二甲基富马酸治疗期间的肠道微生物组变化。
Int J Mol Sci. 2023 Feb 1;24(3):2720. doi: 10.3390/ijms24032720.
本文引用的文献
1
for the Prevention of Type 2 Diabetes and Obesity: A Meta-Analysis of Animal Studies.预防 2 型糖尿病和肥胖：动物研究的荟萃分析。
Nutrients. 2024 Oct 11;16(20):3440. doi: 10.3390/nu16203440.
2
Gut microbial factors predict disease severity in a mouse model of multiple sclerosis.肠道微生物因素可预测多发性硬化症小鼠模型的疾病严重程度。
Nat Microbiol. 2024 Sep;9(9):2244-2261. doi: 10.1038/s41564-024-01761-3. Epub 2024 Jul 15.
3
Identification of commensal gut microbiota signatures as predictors of clinical severity and disease progression in multiple sclerosis.鉴定共生肠道微生物群特征作为多发性硬化症临床严重程度和疾病进展的预测因子。
Sci Rep. 2024 Jul 3;14(1):15292. doi: 10.1038/s41598-024-64369-x.
4
Investigating the metabolite signature of an altered oral microbiota as a discriminant factor for multiple sclerosis: a pilot study.探究口腔微生物群改变的代谢特征作为多发性硬化症的鉴别因素：一项初步研究。
Sci Rep. 2024 Apr 2;14(1):7786. doi: 10.1038/s41598-024-57949-4.
5
Epsilon toxin-producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege.产ε毒素梭状芽孢杆菌定植多发性硬化症肠道微生物组，克服中枢神经系统免疫豁免。
J Clin Invest. 2023 May 1;133(9):e163239. doi: 10.1172/JCI163239.
6
The gut microbiota in multiple sclerosis varies with disease activity.多发性硬化症患者的肠道微生物群与疾病活动度有关。
Genome Med. 2023 Jan 5;15(1):1. doi: 10.1186/s13073-022-01148-1.
7
Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course.多发性硬化症患者和配对的家庭健康对照者的肠道微生物组揭示了与疾病风险和病程的关联。
Cell. 2022 Sep 15;185(19):3467-3486.e16. doi: 10.1016/j.cell.2022.08.021.
8
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms.黏蛋白阿克曼氏菌：新一代有益微生物的范例。
Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):625-637. doi: 10.1038/s41575-022-00631-9. Epub 2022 May 31.
9
Multiple sclerosis patients have an altered gut mycobiome and increased fungal to bacterial richness.多发性硬化症患者的肠道微生物组发生改变，真菌与细菌丰富度比值增加。
PLoS One. 2022 Apr 26;17(4):e0264556. doi: 10.1371/journal.pone.0264556. eCollection 2022.
10
Alterations of the gut mycobiome in patients with MS.多发性硬化症患者肠道微生物组的改变。
EBioMedicine. 2021 Sep;71:103557. doi: 10.1016/j.ebiom.2021.103557. Epub 2021 Aug 26.
Zotero 插件